Generated by AI
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders and rare diseases. The company’s commercial portfolio includes treatments for Parkinson’s disease psychosis and Rett syndrome, reflecting its emphasis on neuropsychiatric and neuro-rare conditions with limited treatment options. Acadia Pharmaceuticals Inc. also maintains a clinical and research pipeline targeting additional unmet needs in neuroscience, including programs in Alzheimer’s disease psychosis, Lewy body dementia psychosis, and other rare or underserved patient populations. Based in San Diego, California, the company serves as a specialized player in the healthcare market, combining drug development, regulatory expertise, and commercialization capabilities to support patients, caregivers, and healthcare providers across its therapeutic areas.
Website12830 El Camino Real
San Diego, CA, 92130
United States
The latest articles about ACAD.
Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.
Acadia Pharmaceuticals (ACAD) stock gains as an appeal court hears oral arguments regarding a patent dispute related to its lead drug, Nuplazid. Read more here.
Summary of Nov 10's posts. Generated by AI.
Summary of Dec 13's posts. Generated by AI.
Summary of Jun 26's posts. Generated by AI.
Summary of Nov 9's posts. Generated by AI.
Investors talking about ACAD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.